Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Reference: Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer - Altai Oncology
  1. Home /
    2. Uncategorized /
  2. New Reference: Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Uncategorized

New Reference: Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

New Reference: Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
Study:
  • Multicenter, open-label, phase 3 trial
  • Advanced endometrial cancer at least one platinum-based chemotherapy
  • Lenvatinib plus pembrolizumab (n=411) or chemotherapy (n=416)
Efficacy:
  • 827 patients (697 pMMR and 130 dMMR)
  • pMMR pts: mPFS: 6.6 vs 3.8 mos (HR:0.60; p<0.001), mOS:17.4 vs 12 months (HR:0.68; p<0.001))
  • All pts: mPFS: 7.2 vs. 3.8 mos (HR: 0.56; p<0.001), mOS:18.3 VS 3.8 months (HR:0.62; p<0.001)
Safety:
  • Hypertension 64.0% vs 5.2%, anemia 26.1% vs 48.7%
  • Grade 3 AE >= 88.9% vs 72.7%

N Engl J Med. 2022 Feb 3;386(5):437-448.

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

https://doi.org/10.1056/nejmoa2108330

Reviewed by Hasan Cagri Yildirim, MD on Mar 28, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More